Disposition of 65403 shares by Kersten Dirk of Dyne Therapeutics at 44.28 subject to Rule 16b-3
DYN Stock | USD 30.61 0.52 1.67% |
About 68% of Dyne Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Dyne Therapeutics suggests that many traders are alarmed. Dyne Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Dyne Therapeutics. Many technical investors use Dyne Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Dyne |
Filed transaction by Dyne Therapeutics Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Dyne Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Dyne Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Dyne Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Dyne Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Dyne Therapeutics Historical Investor Sentiment
Investor biases related to Dyne Therapeutics' public news can be used to forecast risks associated with an investment in Dyne. The trend in average sentiment can be used to explain how an investor holding Dyne can time the market purely based on public headlines and social activities around Dyne Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Dyne Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Dyne Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Dyne Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Dyne Therapeutics.
Dyne Therapeutics Fundamental Analysis
We analyze Dyne Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dyne Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dyne Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Dyne Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Dyne Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dyne Therapeutics stock to make a market-neutral strategy. Peer analysis of Dyne Therapeutics could also be used in its relative valuation, which is a method of valuing Dyne Therapeutics by comparing valuation metrics with similar companies.
Peers
Dyne Therapeutics Related Equities
GLUE | Monte Rosa | 13.72 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
EWTX | Edgewise Therapeutics | 2.48 | ||||
PLRX | Pliant Therapeutics | 2.00 | ||||
STOK | Stoke Therapeutics | 1.68 | ||||
DSGN | Design Therapeutics | 0.50 | ||||
CYTK | Cytokinetics | 0.69 | ||||
RVMD | Revolution Medicines | 1.25 | ||||
ERAS | Erasca | 2.05 | ||||
MLYS | Mineralys Therapeutics, | 2.59 |
Check out Dyne Therapeutics Hype Analysis, Dyne Therapeutics Correlation and Dyne Therapeutics Performance. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.58) | Return On Assets (0.40) | Return On Equity (0.69) |
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.